BriaCell Therapeutics (NASDAQ:BCTX, BCTXW;TSX:BCT) is a medical section biotechnology firm growing progressive immunotherapies for treating most cancers.
With a recently-awarded Quick Observe standing from the FDA, BriaCell’s lead candidate, Bria-IMT™, is an immunotherapy presently being developed to deal with superior breast most cancers, which is the anticipated reason behind over 43,000 deaths within the US in 2022. Bria-IMT™achieved optimistic proof of idea, exhibiting excellent security and efficacy knowledge. Importantly, preliminary efficacy knowledge was related, or superior to, these of different authorized breast most cancers medicine after they have been at an analogous stage of medical improvement. After vital success, BriaCell obtained FDA Quick Observe designation for this focused immunotherapy strategy.
investingnews.com
Firm Highlights
- April 2022: BriaCell receives FDA fast-track approval for focused breast most cancers immunotherapy.
- February 2022: BriaCell appoints famend oncologist, Dr. Giuseppe Del Priore as chief medical officer, appoints immunologist Dr. Alexander Kharazi to its advisory board, and provides two medical trial websites to speed up affected person enrollment.
- December 2021: BriaCell declares insiders’ intention to buy as much as 10 % of public market securities.
- September 2021: BriaCell declares securities buyback to buy as much as 10 % of widespread shares and as much as 10 % of listed warrants.
- July 2021: BriaCell Part I/IIa medical trial mixture research in superior breast most cancers sufferers opens for enrollment.
- June 2021: BriaCell Therapeutics declares closing of US$27.2 million non-public placement
- June 2021: BriaCell Stories 12.0 months total survival profit in superior breast most cancers; one hundred pc decision of ‘eye-bulging’ tumor
- February 2021: BriaCell declares closing of US$25 million public providing and itemizing on NASDAQ.
This BriaCell Therapeutics firm profile is a part of a paid investor training campaitn.*
